Allosteric modulators for adenosine receptors: An alternative to the orthosteric ligands

Current Topics in Medicinal Chemistry

Volumn 10, Issue 10, 2010, Pages 976-992

  la Motta, C ^a   Sartini, S ^a   Morelli, M ^a   Taliani, S ^a   da Settimo, F ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

A1; A2A; A2B; A3; Adenosine; Adenosine receptors; Allosteric modulators

Indexed keywords

4 ANILINO 2 CYCLOPENTYLIMIDAZO[4,5 C]QUINOLINE; 4 METHOXY N [7 METHYL 3 (2 PYRIDINIL) 1 ISOQUINOLINYL]BENZAMIDE; 4 METHOXY N [7 METHYL 3 (2 PYRIDINYL) 1 ISOQUINOLINYL]BENZAMIDE; 4 METHYL 2 OXO 2H CHROMEN 7 YL METHYLCARBAMATE; ADENOSINE; ADENOSINE A1 RECEPTOR; ADENOSINE A2A RECEPTOR; ADENOSINE A2A RECEPTOR AGONIST; ADENOSINE A2B RECEPTOR; ADENOSINE A3 RECEPTOR; ADENOSINE RECEPTOR; G PROTEIN COUPLED RECEPTOR; LIGAND; LUF 6000; N (3,4 DICHLOROPHENYL) 2 (1 ADAMANTANYL) 1H IMIDAZO[4,5 C]QUINOLIN 4 AMINE; N [2,3 DIPHENYL 1,2,4 THIADIAZOL 5(2H) YLIDENE]METHANAMINE; PD 120918; RECEPTOR SUBTYPE; UNCLASSIFIED DRUG;

ALLOSTERISM; ARTICLE; BINDING COMPETITION; DRUG BINDING SITE; DRUG EFFICACY; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SCREENING; HOMEOSTASIS; HUMAN; LIGAND BINDING; NONHUMAN; RECEPTOR UPREGULATION; STEREOCHEMISTRY; STRUCTURE ACTIVITY RELATION;

ADENOSINE; ALLOSTERIC REGULATION; ANIMALS; HUMANS; LIGANDS; PURINERGIC P1 RECEPTOR AGONISTS; RECEPTORS, PURINERGIC P1; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 77953522845     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/156802610791293136     Document Type: Article

References (119)

1. Haskó, G.; Linden, J.; Cronstein, B.; Pacher, P. Adenosine receptors: therapeutic aspects for inflammatory and immune diseases. Nat. Rev. Drug Discov., 2008, 7, 759-770.
2. Fredholm, B. B.; Ijzerman, A. P.; Jacobson, K. A.; Klotz, K. N.; Linden, J. International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol. Rev., 2001, 53, 527-552.
3. Fredholm, B. B.; Arslan, G.; Halldner, L.; Kull, B.; Schulte, G.; Wasserman, W. Structure and function of adenosine receptors and their genes. Naunyn Schmiedebergs Arch. Pharmacol., 2000, 362, 364-374.
4. Jacobson, K. A.; Van Galen, P. J. M.; Michael, W. Adenosine receptors: pharmacology, structure-activity relationships, and therapeutic potential. J. Med. Chem., 1992, 35, 407-422.
5. Fredholm, B. B.; Irenius, E.; Kull, B.; Schulte, G. Comparison of the potency of adenosine as an agonist at human adenosine receptors expressed in Chinese hamster ovary cells. Biochem. Pharmacol., 2001, 61, 443-448.
6. Jacobson, K. A. Introduction to adenosine receptors as therapeutic targets. Handb. Exp. Pharmacol., 2009, 193, 1-24
7. Shryock, J. C.; Belardinelli, L. Adenosine and adenosine receptors in the cardiovascular system: biochemistry, physiology, and pharmacology. Am. J. Cardiol., 1997, 79, 2-10.
8. Guieu, R.; Couraud, F.; Pouget, J.; Sampieri, F.; Bechis, G.; Rochat, H. Adenosine and the nervous system: clinical implications. Clin. Neuropharm., 1996, 19, 459-474.
9. Di Sole, F. Adenosine and renal tubular functions. Curr. Opin. Nephrol. Hypertens., 2008, 17, 399-407.
10. Ye, J. H.; Rajendran, V. M. Adenosine: an immune modulator of inflammatory bowel diseases. World J. Gastroenterol., 2009, 15, 4491-4498.
11. Haskó, G.; Linden, J.; Cronstein, B.; Pacher, P. Adenosine receptors: therapeutic aspects for inflammatory and immune diseases. Nat. Rev. Drug Discov., 2008, 7, 759-770.
12. 2A receptors in inflammation and injury: lessons learned from transgenic animals. J. Leukoc. Biol., 2008, 83, 447-455.
13. 2B adenosine receptors in immunity and inflammation. Trends Pharmacol., 2009, 30, 263-270.
14. Bohr, C.; Hasselbalch, K. A.; Krogh, A. Ubereinen in biologischen beziehung wichtigen einfluss, den die kohlensauerspannung des blutes auf dessen sauerstoffbindung ubt. Skand. Arch. Physiol., 1904, 16, 402-412.
15. Hill, A. V. The possible effects of the aggregation of the molecules of haemoglobin on its dissociation curves. J. Physiol., 1910, 40, iv-vii.
16. Katz, B.; Thesleff, S. A study of the desensitization produced by acetylcholine at the motor end-plate. J. Physiol., 1957, 138, 63-80.
17. Koshland, D. Enzyme flexibility and enzyme action. J. Cell. Comp. Physiol., 1959, 54, 245-258.
18. Monod, J.; Changeux, J.-P.; Jacob, F. Allosteric proteins and cellular control systems. J. Mol. Biol., 1963, 6, 306-329.
19. Monod, J.; Wyman, J.; Changeux, J.-P. On the nature of allosteric transitions: a plausible model. J. Mol. Biol., 1965, 12, 88-118.
20. Christopoulos, A. Allosteric binding sites on cell-surface receptors: novel targets for drug discovery. Nat. Rev. Drug Discov., 2002, 1, 198-210.
21. May, L. T.; Christopoulos, A. Allosteric modulators of G-protein-coupled receptors. Curr. Opin. Pharmacol., 2003, 3, 551-556.
22. Christopoulos, A.; May, L. T.; Avlani, V. A.; Sexton, P. M. G-protein-coupled receptor allosterism: the promise and the problem(s). Biochem. Soc. Trans, 2004, 32, 873-877.
23. Christopoulos, A.; Kenakis, T. G protein-coupled receptor allosterism and complexing. Pharmacol. Rev., 2002, 54, 323-374.
24. Birdsall, N. J. M.; Browning, C.; Hern, J.; Lazareno, S. Allosteric regulation of binding and function at GPCRs. Med. Chem. Res., 2004, 13, 52-62.
25. Soudijn, W.; van Wijngaarden, I.; Ijzerman, P. Allosteric modulation of G protein-coupled receptors. Curr. Opin. Drug Discov. Devel., 2002, 5, 749-755.
26. Gao, Z.-G.; Jacobson, K. A. Allosterism in membrane receptors. Drug Discov. Today, 2006, 11, 191-202.
27. Raddatz, R.; Schaffhauser, E.; Marino M. J. Allosteric approaches to the targeting of G-protein-coupled receptors for novel drug discovery: a critical assessment. Biochem. Pharmacol., 2007, 74, 383-391.
28. Bokoch, M. P.; Zou, Y.; Rasmussen, S. G. F.; Liu, C. W.; Nygaard, R.; Rosenbaum, D. M.; Fung, J. J.; Choi, H.-J.; Thian, F. S.; Kobilka, T. S.; Puglisi, J. D.; Weis, W. I.; Pardo, L.; Prosser, R. S.; Mueller, L.; Kobilka, B. K. Ligand-specific regulation of the extracellular surface of a G-protein-coupled receptor. Nature, 2010, 463, 108-112.
29. May, L. T.; Leach, K.; Sexton, P.k M.; Christopoulos A. Allosteric modulation of G protein-coupled receptors. Annu. Rev. Pharmacol. Toxicol., 2007, 47, 1-51.
30. May, L. T.; Avlani, V. A.; Sexton, P. M.; Christopoulos, A. Allosteric modulation of G protein-coupled receptors. Curr. Pharm. Des., 2004, 10, 2003-2013.
31. Gao, Z.-G-; Kim, S.-K.; IJzerman, A. P.; Jacobson, K. A. Allosteric modulation of the adenosine family of receptors. Mini-Rev. Med. Chem., 2005, 5, 545-553.
32. 1 adenosine receptor. Mini Rev. Med. Chem., 2007, 7, 559-569.
33. Goeblyoes, A.; IJzerman, A. P. Allosteric modulation of adenosine receptors. Purinergic Sign., 2009, 5, 51-61.
34. 1 adenosine receptors. FASEB J., 1991, 5, 2668-2676.
35. 3 adenosine receptor agonists: an overview. Exp. Opin. Ther. Pat., 1999, 9, 515-527.
36. 1 receptor: analysis of the potential therapeutic effects obtained by its activation in the central nervous system. Curr. Med. Chem., 2002, 9, 1923-1937.
37. 1 receptors: partial and inverse agonism. Curr. Pharm. Des., 2002, 8, 2333-2344.
38. 1 adenosine receptor ligands. Curr. Topics Med. Chem., 2003, 3, 369-385.
39. 1 receptor binding by 2-amino-3-benzoylthiophenes. Mol. Pharmacol., 1990, 38, 950-958.
40. Tinney, F. J.; Sanchez, J. P.; Nogas, J. A. Synthesis and pharmacological evaluation of 2,3-dihydro-1H-thieno [2,3-e] [1,4] diazepines. J. Med. Chem., 1974, 17, 624-630.
41. 1 receptor binding and function by 2-amino-3-benzoylthiophenes. Mol. Pharmacol., 1990, 38, 939-949.
42. 2A adenosine receptor coupling with Gs. Biochem. J., 2006, 396, 139-146.
43. 1 receptor. Eur. J. Pharmacol., 2005, 510, 1-8.
44. 1 receptor. Biochem. Pharmacol., 2001, 61, 137-144.
45. 1 receptor allosteric enhancer PD 81,723 on agonist binding to brain and adipocyte membranes. Brain Res., 1999, 840, 75-83.
46. 1 receptor. Am. J. Physiol., 1993, 264, H1017-H1022.
47. 1 receptor enhancer of the negative dromotropic action of adenosine in the guinea pig heart. J. Pharmacol. Exp. Ther., 1993, 266, 611-617.
48. Kollias-Baker, C.; Ruble, J.; Dennis, D.; Bruns, R. F.; Linden, J.; Belardinelli, L. Allosteric enhancer PD81,723 acts by novel mechanism to potentiate cardiac actions of adenosine. Circ. Res., 1994, 75, 961-971.
49. Kollias-Baker, C.; Xu, J.; Pelleg, A.; Belardinelli, L. Novel approach for enhancing atrioventricular nodal conduction delay mediated by endogenous adenosine. Circ. Res., 1994, 75, 972-980.
50. 1 receptor functions by benzoylthiophenes in guinea pig tissues in vitro. Naunyn Schmiedeberg's Arch. Pharmacol., 1995, 352, 206-212.
51. Dennis, D. M.; Raatikainen, M. J.; Martens, J. R.; Belardinelli, L. Modulation of atrioventricular nodal function by metabolic and allosteric regulators of endogenous adenosine in guinea pig heart. Circulation, 1996, 94, 2551-2559.
52. 1 adenosine receptor, lowers the threshold for ischemic preconditioning in dogs. Circ. Res., 1996, 79, 415-423.
53. 1 receptor. Synthesis and biological evaluation of novel 2-amino-3-benzoylthiophenes as allosteric enhancers of agonist binding. J. Med. Chem., 1999, 42, 3629-3635.
54. Topliss, J. G. Utilization of operational schemes for analogue synthesis in drug design. J. Med. Chem., 1972, 15, 1006-1011.
55. 1 receptors. Drug Dev. Res., 2000, 49, 227-237.
56. Li, X.; Conklin, D.; Ma, W.; Zhu, X.; Eisenach, J. C. Spinal noradrenergic activation mediates allodynia reduction from an allosteric adenosine modulator in a rat model of neuropathic pain. Pain., 2002, 97, 117-125.
57. Li, X.; Conklin, D.; Pan, H.-L.; Eisenach, J. C. Allosteric adenosine receptor modulation reduces hypersensitivity following peripheral inflammation by a central mechanism. J. Pharmacol. Exp. Ther., 2003, 305, 950-955.
58. 1 allosteric enhancer. Bioorg. Med. Chem. Lett., 2006, 16, 1402-1404.
59. 1-adenosine receptor. Bioorg. Med. Chem. Lett., 2000, 10, 1953-1957.
60. 1 adenosine receptor. J. Med. Chem., 2003, 46, 794-809.
61. 1 receptor. Bioorg. Med. Chem. Lett., 2006, 16, 5530-5533.
62. 1 receptor. Eur. J. Med. Chem., 2004, 39, 855-865.
63. 1 adenosine receptors. J. Med. Chem., 2002, 45, 382-389.
64. 1 adenosine agonist binding: new 3, 4-, and 5-modifications. J. Med. Chem., 2003, 46, 1870-1877.
65. 1 receptor allosteric enhancers. Bioorg. Med. Chem., 2006, 14, 2358-2365.
66. 1 receptor: synthesis and pharmacological evaluation of 4-substituted 2-amino-3-benzoylthiophenes. J. Med. Chem., 2009, 52, 4543-4547.
67. 1 adenosine receptors. Bioorg. Med. Chem. Lett., 2002, 12, 1563-1566.
68. Göblyös, A.; Santiago, S. N.; Pietra, D.; Mulder-Krieger, T.; von Frijtag Drabbe Künzel, J.; Brussee, J.; IJzerman, A. P. Synthesis and biological evaluation of 2-aminothiazoles and their amide derivatives on human adenosine receptors. Lack of effect of 2-aminothiazoles as allosteric enhancers. Bioorg. Med. Chem., 2005, 13, 2079-2087.
69. 1 adenosine receptor agonist allosteric enhancers having improved potency. J. Med. Chem., 2005, 48, 5131-5139.
70. Fawzi, A. B.; Macdonald, D.; Benbow, L. L.; Smith-Torhan, A.; Zhang, H.; Weig, B. C.; Ho, G.; Tulshian, D.; Linder, M. E.; Graziano, M. P. SCH202676: an allosteric modulator of both agonist and antagonist binding to G protein-coupled receptors. Mol. Pharmacol., 2001, 59, 30-37.
71. Gao, Z.-G.; Gross, A. S.; Jacobson, K. A. Effects of the allosteric modulator SCH-202676 on adenosine and P2Y receptors. Life Sci., 2004, 74, 3173-3180.
72. Van den Nieuwendijk, A. M. C. H.; Pietra, D.; Heitman, L.; Göblyös A.; IJzerman, A. P. Synthesis and biological evaluation of 2,3,5-substituted [1,2,4]thiadiazoles as allosteric modulators of adenosine receptors. J. Med. Chem., 2004, 47, 663-672.
73. 1 receptors and their molecular mechanism of action. J. Med. Chem., 2005, 48, 1145-1151.
74. 1 receptor allosteric modulators and antagonists. J. Med. Chem., 2008, 51, 6165-6172.
75. 1 adenosine receptor allosteric modulators and antagonists. Bioorg. Med. Chem., 2009, 17, 7353-7361.
76. 1 adenosine receptor: abolishment of negative cooperativity for [3H](R)-PIA binding to the caudate nucleus. J. Neurochem., 2008, 107, 161-170.
77. 3H]NECA in rat striatal membranes. Mol Pharmacol., 1986, 29, 331-346.
78. 2A-adenosine receptor: a GPCR with unique features? Br. J. Pharmacol., 2008, 153, S184-S190.
79. 2A receptors. Curr. Pharm. Des., 2008, 14, 1698-1722.
80. 2A adenosine receptor and its modulators: overview on a druggable GPCR and on structure-activity relationship analysis and binding requirements of agonists and antagonists. Curr. Pharm. Des., 2008, 14, 1525-1552.
81. 2A adenosine receptor agonists ATL193 and ATL146e administered by either intra-venous infusion or bolus injection. Circulation, 2001, 104, 1181-1187.
82. 2A receptor: promises, problems and potential solutions. Br. J. Pharmacol., 2008, 155, 463-474.
83. 2A receptors in psycho-pharmacology: modulators of behavior, mood and cognition. Curr. Neuropharmacol., 2009, 7, 195-206.
84. 2A receptors in Parkinson's disease treatment. Purinergic Signal., 2008, 4, 305-312.
85. Bruns, R. F.; Lu, G. H. In Adenosine receptors in the nervous system. Ribeiro, J. A. Ed.; Taylor and Francis. London, 1989, p. 192.
86. 2A adenosine receptors by amiloride analogues and sodium ions. Biochem. Pharmacol., 2000, 60, 669-676.
87. 2A receptor. Critical involvement of Glu13 in agonist recognition. Eur. J. Pharmacol., 1996, 310, 269-272.
88. 2A adenosine receptors. involvement of Glu13 and His278 in ligand binding and sodium modulation. Biochem. Pharmacol., 2000, 60, 661-668.
89. 3 adenosine receptors. Biochem Pharmacol., 2003, 65, 525-534.
90. 2A adenosine receptors. Eur. J. Med. Chem., 2008, 43, 1639-1647.
91. 2B adenosine receptors. Curr. Top. Med. Chem., 2003, 3, 427-443.
92. 2B receptors as therapeutic targets. Drug Dev. Res., 1998, 45, 198-206.
93. 2B adenosine receptor agonists. Purinergic Signal., 2008, 4, 287-303.
94. 2B adenosine receptor antagonists: recent developments. Mini-Rev. Med. Chem., 2005, 5, 1053-1060.
95. 2B receptor is highly expressed in human hepatocellular carcinoma. Hepatol. Res., 2006, 36, 56-60.
96. 2+ signal. Br. J. Pharmacol., 2005, 145, 211-218.
97. 2B receptor. J. Med. Chem., 2001, 44, 170-179.
98. 2B adenosine receptors. Purinergic Signal., 2006, 2, 583-588.
99. 2B receptors. Biochem. Pharmacol., 2004, 68, 305-312.
100. 2B adenosine receptors. Bioorg. Med. Chem. Lett., 2004, 14, 3607-3610.
101. 2B receptors. Biochem. Pharmacol., 2005, 70, 1601-1612.
102. 2B adenosine receptors. Biochem. Pharmacol., 2001, 61, 657-663.
103. 3 adenosine receptor. Proc. Natl. Acad. Sci. USA, 1992, 89, 7432-7436.
104. Kaiser, S. M.; Quinn, R. J. Adenosine receptors as potential therapeutic targets. Drug Discov. Today, 1999, 4, 542-551.
105. 3 adenosine receptor: pharmacology and role in disease. Handb. Exp. Pharmacol., 2009, 193, 297-327.
106. 3 adenosine receptor: an enigmatic player in cell biology. Pharmacol. Ther., 2008, 117, 123-140.
107. 3 receptor subtype. Curr. Top. Med. Chem., 2003, 3, 463-469.
108. 3 adenosine receptor as a target for cancer therapy. Anticancer Drugs, 2002, 13, 437-443.
109. 3 adenosine receptor-mediated protection of the ischemic heart. Vascul. Pharmacol., 2005, 42, 271-279.
110. 3 receptor ligands. 1. 3-(2-Pyridinyl)isoquinoline derivatives. J. Med. Chem., 1998, 41, 3987-3993.
111. 3 adenosine receptors by a series of 3-(2-pyridinyl)isoquinoline derivatives. Mol. Pharmacol., 2001, 60, 1057-1063.
112. Van Galen, P. J. M.; Nissen, P.; van Wijngaargen, I.; IJzerman, A. P.; Soudijn, W. 1H-imidazo [4,5-c]quinolin-2-amines: novel non-xanthineadenosine antagonists. J. Med. Chem., 1991, 34, 1202-1206.
113. 3 adenosine receptors by a series of imidazoquinoline derivatives. Mol. Pharmacol., 2002, 62, 81-89.
114. 3 adenosine receptor. J. Med. Chem., 2006, 49, 3354-3361.
115. 3 adenosine receptor by the imidazoquinoline allosteric enhancer LUF6000. BMC Pharmacol., 2008, 8, 20-30.
116. 3 adenosine receptor. J. Med. Chem., 2009, 52, 2098-2108.
117. Horstman, D. A.; Brandon, S.; Wilson, A. L.; Guyer, C. A.; Cragoe, E. J. Jr.; Limbird, L. E. J. Biol. Chem., 1990, 265, 21590-21595.
118. Gao, Z.-G.; Kim, S. K.; Gross, A. S.; Chen, A.; Blaustein, J. B.; Jacobson, K. A. Mol. Pharmacol., 2003, 63, 1021-1031.
119. 3 adenosine receptor. Biochem. Pharmacol., 2010, 79, 48-56.